Greater Regulatory Scrutiny Could Weigh on Biotech ETFs

by | Mar 24, 2021 | BioTech Stocks, Outside Takes, Tech Stocks

This is originally from post published on on ETFTrends.com.

Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) and SPDR S&P Biotech ETF (NYSEArca: XBI) both decreased 5.8% while the iShares Nasdaq Biotechnology ETF (IBB), the largest biotech-related ETF by assets, fell […]

The post Greater Regulatory Scrutiny Could Weigh on Biotech ETFs appeared first on ETF Trends.


This is originally from post published on on ETFTrends.com.

>

Pin It on Pinterest

Share This